Clene’s Strategic Financial Management and Promising Clinical Developments Drive Buy Rating

Maxim Group analyst Naz Rahman has reiterated their bullish stance on CLNN stock, giving a Buy rating yesterday.

Naz Rahman has given his Buy rating due to a combination of factors including Clene’s strategic financial management and promising clinical developments. Clene has reported a manageable net loss and has secured a $25 million ATM agreement, which, along with reduced expenses, provides a financial runway into the third quarter of 2025. This financial stability supports Clene’s efforts to advance its lead asset, CNM-Au8, towards a New Drug Application (NDA) filing for amyotrophic lateral sclerosis (ALS) in the fourth quarter of 2025.
Clene’s CNM-Au8 has received Orphan Drug Designation, which qualifies it for Priority Review, potentially expediting its approval process. The company is actively working on neurofilament light chain (NfL) data analysis, expected to be completed in the third quarter of 2025, which is crucial for the NDA submission. The anticipated approval and launch of CNM-Au8 in 2026, along with potential applications in multiple sclerosis and Parkinson’s disease, contribute to the positive outlook. These factors, combined with a strategic approach to clinical trials and regulatory engagements, underpin Rahman’s optimistic Buy rating for Clene.

Rahman covers the Healthcare sector, focusing on stocks such as Galmed Pharmaceuticals, Nuvectis Pharma, and Cingulate Inc. According to TipRanks, Rahman has an average return of -23.2% and a 23.00% success rate on recommended stocks.

In another report released yesterday, JonesTrading also reiterated a Buy rating on the stock with a $30.00 price target.